2-Fluoro-1-isopropyl-4-nitrobenzene | 1369836-94-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Fluoro-1-isopropyl-4-nitrobenzene
• 英文别名: 2-fluoro-4-nitro-1-propan-2-ylbenzene
• CAS: 1369836-94-1
• 化学式: C9H10FNO2
• 分子量: 183.18
• InChiKey: MEKNILQFRBZDJJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] 5, 6-DIHYDRO-11H-INDOLO [2, 3-B] QUINOLIN-11-ONE COMPOUNDS AS ALK INHIBITORS<br/>[FR] COMPOSÉS DE 5, 6-DIHYDRO-11H-INDOLO [2, 3-B] QUINOLÉIN-11-ONE UTILES EN TANT QU'INHIBITEURS D'ALK
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2019179482A1

  公开（公告）日：2019-09-26

  The present disclosure provides compounds represented by Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, R8, E, Z, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

  本公开提供了由式（I）表示的化合物及其药用可接受的盐和溶剂，其中R1a、R1b、R2a、R2b、R3、R4、R5、R6、R7、R8、E、Z等如规范中所定义。本公开还提供了式（I）的化合物，用于治疗对ALK抑制有响应的疾病或疾病，如癌症。
• Glycopeptide Antibiotic Monomer Derivatives
  申请人：Arimoto Hirokazu

  公开号：US20080097078A1

  公开（公告）日：2008-04-24

  Novel glycopeptide antibiotic derivatives. These derivatives are represented by the formula (aglycon part of glycopeptide antibiotic derivative)-(Sac-NH)—R A [wherein (aglycon part of glycopeptide antibiotic derivative) is the part formed by removing the sugar part from a known glycopeptide antibiotic derivative; (Sac-NH) part is an amino sugar part or a sugar chain part containing an amino sugar; and R A represents, e.g., the formula —X 1 —Ar 1 —X 2 —Y—X 3 —Ar 2 (wherein X 1 , X 2 , and X 3 each represents 1) a single bond or 2) a heteroatom or heteroatom-containing group selected from the group consisting of —N═, ═N—, —NR 1 —, —O—, etc.; Y represents —NR 2 CO— or —CONR 2 — (wherein R 2 represents hydrogen or lower alkyl), etc.)]. These derivatives have antibacterial activity against vancomycin-resistant bacteria.
• OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING
  申请人：Suzuki Hideyuki

  公开号：US20100256355A1

  公开（公告）日：2010-10-07

  The present invention provides a novel oxazolidinone derivative of the formula (I): wherein Ring A is (A-1) a 7-membered monocyclic heterocycle containing three N atoms; (A-2) a 7-membered monocyclic heterocycle containing two N atoms and one O atom; or (A-3) a 7-membered monocyclic heterocycle containing two N atoms and one S atom, SO or SO 2 , wherein said monocyclic heterocycle is optionally substituted, optionally unsaturated and optionally fused with another ring; X 1 is a single bond, or a heteroatom-containing group selected from the group consisting of —O—, —S—, —NR 2 —, —CO—, —CS—, —CONR 3 —, —NR 4 CO—, —SO 2 NR 5 —, and —NR 6 SO 2 —, wherein R 2 , R 3 , R 4 , R 5 and R 6 are independently hydrogen or lower alkyl, or lower alkylene or lower alkenylene each optionally interrupted by said heteroatom-containing group; Ring B is optionally substituted carbocycle or optionally substituted heterocycle; and R 1 is hydrogen, or an organic residue which is able to bind to the 5 -position of the oxazolidinone ring in oxazolidinone antimicrobial agents, pharmaceutically acceptable salts and solvates thereof which are useful as an antibacterial agent.
• 5,6-DIHYDRO-1 1H-INDOLO{2,3-B}QUINOLIN- 11-ONE COMPOUNDS AS ALK INHIBITORS
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20210087188A1

  公开（公告）日：2021-03-25

  The present disclosure provides compounds represented by Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R 1a , R 1b , R 2a , R 2b , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , E, Z, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
• US7329663B2
  申请人：——

  公开号：US7329663B2

  公开（公告）日：2008-02-12